Shorts

In a conversation with CancerNetwork®, Sivraj Muralikrishnan, MD, discussed how findings from the phase 3 LIBRETTO-432 trial (NCT04819100) presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting may influence the treatment of patients with RET fusion-positive non–small cell lung cancer (NSCLC).

0:55

What Does LIBRETTO-432 Mean for Precision Oncology in RET+ NSCLC?

2 months ago

Sivraj Muralikrishnan, MD

In this video, Benoit Tessoulin, MD, PhD, hematologist at Centre Hospitalier Universitaire de Nantes, Nantes, France, discussed the potential of combining epcoritamab plus lenalidomide and rituximab for patients with follicular lymphoma experiencing a relapse after first-line chemoimmunotherapy.

0:41

How the EPCORE FL-1 Regimen is Changing the Follicular Lymphoma Landscape

2 months ago

Benoit Tessoulin, MD, PhD

In a conversation with CancerNetwork® at the opening of the Melchiorre Cancer Center at Cooperman Barnabas Medical Center, a new cancer facility from RWJBarnabas Health and Rutgers Cancer Institute, Steven K. Libutti, MD, FACS, highlighted how the center will facilitate seamless multidisciplinary collaboration to enhance patient care.

1:00

Designing a New Cancer Center to Facilitate Seamless Teamwork

2 months ago

Steven K. Libutti, MD

Guilherme Perini, MD, PhD, explained how dual checkpoint inhibition serves as a proof of concept for reversing immunotherapy resistance while preserving quality of life in heavily pretreated classic Hodgkin lymphoma.

1:08

Prioritizing Response Durability in Heavily Pretreated Hodgkin Lymphoma

2 months ago

Guilherme Fleury Perini, MD, PhD

Chinmay Jani, MD, joined CancerNetwork® in the studio to discuss ongoing work dedicated to overcoming immunotherapy resistance and harnessing novel biomarkers to elevate the quality of care for patients with lung cancer.

0:34

Can Lung Cancer Become a Chronic Disease?

2 months ago

Chinmay Jani, MD

0:35

Building a “Layer of Ethics” Into Oncologic AI Tools

2 months ago

Chinmay Jani, MD

Matthew Matasar, MD, noted that while the frontMIND regimen has caught everyone’s attention, the lack of a statistically significant overall survival benefit means treating oncologists must carefully balance efficacy against incremental adverse effects and scheduling burdens.

0:49

Weighing the frontMIND PFS Benefit Vs Toxicity in High-Risk DLBCL

2 months ago

Matthew J. Matasar, MD

Eric Miller, MD, discussed clinical thresholds that may prompt the adoption of a bladder-sparing approach among patients with urothelial carcinoma.

1:01

Patient Values Inform Treatment Decision-Making in Urothelial Carcinoma

2 months ago

Eric Miller, MD

0:51

Exploring the Weight Loss Potential of GLP-1 Agonists in Patients With Breast Cancer

2 months ago

Sherry Shen, MD

1:22

How GLP-1 Agonists Improve Overall Survival in Breast Cancer Care

3 months ago

Sherry Shen, MD

Yan Leyfman, MD, broke down a review article titled “Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma”, which was published in the journal ONCOLOGY in May 2026.

0:58

Investigating the Evolution of Cellular Therapy in Multiple Myeloma

3 months ago

Yan Leyfman, MD

Bachy noted that the initiation of the phase 3 MorningLyte trial (NCT06284122) was directly inspired by the phase 1b results, expressing that the same mosunetuzumab regimen was being compared against conventional chemoimmunotherapy.

0:57

Phase 1 Mosunetuzumab Data Inspires Phase 3 MorningLyte Study

3 months ago

1:03

How is CAR T-Cell Therapy Transforming Expectations in Multiple Myeloma?

3 months ago

Yan Leyfman, MD

1:11

How a Nurse Builds Deep Trust with Patients

3 months ago

Kassiane Saieed, DNP, AGNP-C

In a conversation with CancerNetwork® at the European Hematology Association (EHA) 2026 Congress, Matthew S. Davids, MD, MMSc, discussed what updated findings from the phase 3 BRUIN CLL-322 trial (NCT04965493) represent for the clinical utility of pirtobrutinib (Jaypirca) plus venetoclax (Venclexta) and rituximab (Rituxan; PVR) for patients with previously treated chronic lymphocytic leukemia.

0:48

When is Pirtobrutinib Triplet Therapy Most Useful in CLL Care?

3 months ago

Matthew S. Davids, MD, MMSc

1:22

Why Fertility Talks Can’t Wait After a Cancer Diagnosis

3 months ago

Kassiane Saieed, DNP, AGNP-C

Jorge E. Cortes, MD, spoke with CancerNetwork® about updated findings from the phase 3 ASC4FIRST trial (NCT04971226) showing improved responses and tolerability with asciminib (Scemblix) vs other tyrosine kinase inhibitors like imatinib (Gleevec) among those with chronic myeloid leukemia in chronic phase (CML-CP).

0:58

Perseverance is Key With Asciminib in Chronic Myeloid Leukemia

3 months ago

Jorge E. Cortes, MD

Karen Reckamp, MD, MS, challenged leadership to move beyond traditional, volume-based work relative value unit (wRVU) metrics.

0:52

Reexamining Investigator Incentives for Clinical Research Beyond RVUs

3 months ago

Karen L. Reckamp, MD

0:51

Will Multi-Targeted Regimens Spell a Reduction of Chemotherapy in DLBCL?

3 months ago

Sonali M. Smith, MD

0:50

Can Tafasitamab/Lenalidomide Prolong Remission in High-Risk DLBCL?

3 months ago

Sonali M. Smith, MD

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Hannah Goulart, MD, spoke about findings from an analysis evaluating revumenib (Revuforj) maintenance after allogeneic stem cell transplantation among patients with acute myeloid leukemia.

0:35

Does Revumenib Have a Role in The Pediatric AML Setting?

3 months ago

Hannah Goulart, MD

David M. Waterhouse, MD, MPH, discussed findings from a chart review analysis, contextualized by a need to improve prostate cancer testing rates in the US.

Developing Governance for AI in Prostate Cancer Genetic Testing

3 months ago

David M. Waterhouse, MD, MPH

0:54

How Does Vorasidenib Impact the Tumor Microenvironment?

3 months ago

Timothy F. Cloughesy, MD

Fred Saad, MD, FRCS, CQ, FCAHS, stated that no significant differences in higher grade or serious adverse effects emerged among patients regardless of disease volume.

1:06

AE Profile of Lu-177-PSMA-617 Similar Among Low, High Volume mHPSC Groups

3 months ago

Fred Saad, MD

Praful Ravi, MB, BChir, MRCP, highlighted that residual PSMA-avid disease remained detectable on PET imaging in 100% of patients with metastatic HSPC at the 6-month mark.

0:59

PSMAtrack: 100% of mHSPC Group Show Residual PSMA-Avid Disease at 6 Months

3 months ago

Praful Ravi, MB, BChir, MRCP

0:30

How Does Abemaciclib Toxicity Translate from Breast to Gynecologic Cancers?

3 months ago

Jordyn Silverstein, MD

0:49

ADC Vs Standard Chemo Selection in Breast Cancer

3 months ago

Paolo Tarantino, MD, PhD

According to Nicholas Hornstein, MD, PhD, although it broke headlines last year, this year’s presentation for the BREAKWATER trial will be a victory lap.

1:19

What to Expect From the BREAKWATER Trial at ASCO 2026?

3 months ago

Nicholas James Hornstein, MD, PhD

0:55

Personalized Vaccine/Pembrolizumab: The ASCO Abstract to Watch in Glioblastoma

3 months ago

Sonikpreet Aulakh, MBBS, MD

As part of a program conducted at the University of Miami, researchers utilized the Laravel AI platform to identify patient cases and cross-trial comparisons within their platform.

1:11

AI in Cross-Trial Comparison: Optimizing Meta-Analyses in Oncology

3 months ago

Chinmay Jani, MD

Shorts

Trending on CancerNetwork

Novel Agent Earns FDA Breakthrough Therapy Designation for HPV+ Oropharyngeal Cancer

Debating Camizestrant, ctDNA Monitoring, and SERENA-6 in HR+ Breast Cancer

Signatera ctDNA Test Shows Superior MRD Assessment in Lymphoma

Saturated Fat Intake Linked to Greater Mortality in Nonmetastatic Prostate Cancer

Zanidatamab Plus Chemotherapy Extends OS in First-Line HER2+ Advanced GEA